louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05977452: The Risk Assessment Scale for Peripherally Inserted Central Venous Catheter (PICC) Related Thrombosis in Cancer Patients
Official title: The Risk Assessment Scale for Peripherally Inserted Central Venous Catheter (PICC) Related Thrombosis in Cancer Patients :A Prospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thrombosis
Catheter
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2023-08-04
Enrollment: 281
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cancer patients with PICC placement in Sun Yat-sen University Cancer Center

Brief summary: The aim of this study is to compare the accuracy and clinical predictive value of the Michigan Risk Score, Caprini Risk Assessment Model , and Maneval Scale （Chinese version）in predicting PICC-related thrombosis.

Detailed description: The aim of this study is to compare the accuracy and clinical predictive value of the Michigan Risk Score, Caprini Risk Assessment Model , and Maneval Scale（Chinese version） in predicting PICC-related thrombosis.

Patients who will receive PICC placement will be evaluated by using the Michigan Risk Score, Caprini Risk Assessment Model , and Maneval Scale the day during PICC placement, 24-48h after PICC placement and every time patients receive PICC maintenance.

Eligibility criteria: Inclusion Criteria:

* Cancer patients
* Older than 18 years
* Being able to complete the questionnaire independently
* Patients who need PICC for treatment
* Being able to perform catheter maintenance in the hospital of admission until catheter removal
* Patients who agree to participate and sign the consent form

Exclusion Criteria:

* Patients who were or suspected to be allergic to the ingredients contained in PICC
* PICC placed in the lower extremity

Primary outcomes:
measure: PICC thrombosis
timeFrame: through study completion，up to 1 year
measure: The Michigan Risk Score
timeFrame: From date of PICC catheterization until the date of PICC removal or date of occurrence of PICC related thrombosis, whichever came first, assessed up to 12 months.
measure: Maneval Scale
timeFrame: From date of PICC catheterization until the date of PICC removal or date of occurrence of PICC related thrombosis, whichever came first, assessed up to 12 months.
measure: Caprini Risk Assessment Model
timeFrame: From date of PICC catheterization until the date of PICC removal or date of occurrence of PICC related thrombosis, whichever came first, assessed up to 12 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: The Catheter Clinic
Study officials:
References:
Clinical trial NCT02455752: Laparoscopic Extraperitoneal Total Mesorectal Excision (LE-TME): A New Feasible Technical Approach.
Official title: Laparoscopic Extraperitoneal Total Mesorectal Excision (LE-TME): A New Feasible Technical Approach.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Total Mesorectal Excision
Laparoscopic
Keywords: LE-TME
Laparoscopic rectal resection
Retroperitoneal resection
Lead sponsor: Mansoura University
Sponsor class: OTHER
Collaborators: name: West oncologic center, Nantes, France
name: Gustave Roussy, Cancer Campus, Grand Paris
First posted: 2015-05-28
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study involves the use of Retroperitoneal plane for TME for rectal anterior resection. Through a pilot prospective study, LR-TME will be assessed as one arm study.

Detailed description: This study is based on our new suggested theory for a retro-peritoneal approach. After successful 2 cases of Laparoscopic extraperitoneal-TME. A pilot study for assessment of the feasibilty of the new approach.

Data will be registered prospectively and the perioperative outcomes will be assessed.

Eligibility criteria: Inclusion Criteria:

* (Rectum, Anal or sigmoid) Malignancy requiring mesorectal excision and Fit for laparoscopic surgery

Exclusion Criteria:

* contraindication to laparoscopic surgery-unwilling to participate in the clinical trial.

Primary outcomes:
measure: Feasibility of the procedure
timeFrame: 1 day
Secondary outcomes:
measure: Intraoperative morbidity
timeFrame: 1 day
measure: Postoperative morbidity
timeFrame: Till patient discharge
measure: Pathologic report outcome
timeFrame: 7 days
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Oncology center of mansoura university
state: Eldakahlia
Study officials:
affiliation: 1-Assistant lecturer of surgical oncology, Mansoura university Egypt. 2-Research Fellow, Policlinico Umberto primo, LA SAPIENZA, Roma, Italy.
name: Osama Eldamshety, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: 1- Department of Digestive Oncological surgery, West oncologic center, Nantes, France 2- Department of digestive Oncological surgery, Gustave Roussy Cancer Campus, Villejuif, France
name: Frédéric Dumont, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00230152: Hybrid Imaging Modalities for the Evaluation of Infection
Official title: Nuclear Medicine for the Evaluation of Infection-the Added Value of Hybrid Imaging Modalities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infectious Diseases
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2005-09-30
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The synergistic value of the fusion of physiologic and anatomical data has been described using several co-registration techniques for various nuclear medicine procedures and morphologic imaging modalities (single photon emission computed tomography-computed tomography \[SPECT-CT\], SPECT-magnetic resonance imaging \[MRI\], camera-based positron emission tomography \[PET\]-CT and PET-CT). The researchers hypothesize that fusion of nuclear medicine (NM) and CT data acquired sequentially in a single imaging session on one device is clinically superior to side-by-side evaluation of separately performed imaging tests. They hypothesize that more accurate localization of increased radiotracer activity on NM procedures will improve the diagnostic accuracy for detection of infection and will subsequently have a significant impact on patient management.

The purpose of the present study is to assess the clinical value of this new technology of fused imaging in patients undergoing diagnostic nuclear medicine evaluation for suspicion of an infection process.

Detailed description: The researchers hypothesize that fusion of nuclear medicine (NM) and CT data acquired sequentially in a single imaging session on one device is clinically superior to side-by-side evaluation of separately performed imaging tests. They hypothesize that more accurate localization of increased radiotracer activity on NM procedures will improve the diagnostic accuracy for detection of infection and will subsequently have a significant impact on patient management.

The purpose of the present study is to assess the clinical value of this new technology of fused imaging in patients undergoing diagnostic nuclear medicine evaluation for suspicion of an infection process.

Eligibility criteria: Inclusion Criteria:

* Patients referred for NM imaging procedures to assess the presence of infectious processes.
* Patients signed informed consent

Exclusion Criteria:

* The study will not be performed in pregnant or lactating women.
* Patients unable or unwilling to tolerate the scan until its completion

Primary outcomes:
measure: The impact of the imaging modality on patient management
timeFrame: 3 years
Secondary outcomes:
measure: The impact of the imaging modality on patient management
timeFrame: 2 years
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Medical Center
Study officials:
affiliation: Rambam Health Care Campus
name: Zohar Keidar, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01227252: A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
Official title: Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Alzheimer's Disease
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2010-10-25
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.


Eligibility criteria: Inclusion Criteria:

* Healthy men and non-childbearing potential women
* Body mass index between 18.0-32.0 kilograms per square meter (kg/m\^2)
* Are reliable and willing to make yourself available for the duration of the study and are willing to follow study procedures and research unit policies

Exclusion Criteria:

* Taking over-the-counter or prescription medication with the exception of vitamins or minerals
* Smoke more than 10 cigarettes per day
* Drink more than 5 cups of caffeine containing beverages (for example, coffee, tea) per day

Primary outcomes:
measure: Number of Participants With Clinically Significant Effects
timeFrame: Predose up to Day 70
Secondary outcomes:
measure: Plasma Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY2886721
timeFrame: Predose (Day 14) up to Day 19
measure: Plasma Area Under the Concentration Versus Time Curve (AUC) of LY2886721
timeFrame: Predose (Day 14) to 24 Hours post-dose (Day 15)
measure: Plasma Amyloid Beta (Aβ) 1-40 Concentration
timeFrame: Predose (Day 14) up to Day 19
measure: Cerebrospinal Fluid (CSF) Concentration of LY2886721
timeFrame: 24 Hours post-dose (Day 15)
measure: Change From Baseline to Day 15 Endpoint in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ) 1-40 Concentration
timeFrame: Predose (Day 14), 24 Hours post-dose (Day 15)
Other outcomes:
Locations:
city: Glendale
country: United States
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
state: California
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05293652: Effect of Hydrocortisone Iontophoresis Versus Hydrocortisone Phonophoresis On Post Surgical Scar
Official title: Effect of Hydrocortisone Iontophoresis Versus Hydrocortisone Phonophoresis On Post Surgical Scar
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Scar
Hydrocortisone
Iontophoresis
Phonophoresis
Lead sponsor: Horus University
Sponsor class: OTHER
First posted: 2022-03-24
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study will be to compare the effect of hydrocortisone iontophoresis and hydrocortisone phonophoresis on the treatment of surgical scar and overall scar appearance.

Detailed description: Scar contractures develop and extend to the underlying connective tissue and then muscles, leading to reduction in joint range of motion and affecting the day-to-day activities.

Most patients (irrespective of age, gender and ethnicity) believe that even a small improvement in scarring is worthwhile , any research that may help improve scar outcome is meaningful.

The need of this study has developed from the rarity of information about the difference between the effectiveness of iontophoresis and phonophoresis in enhancing the overall appearance of surgical scar.

Eligibility criteria: Inclusion Criteria:

* Both genders
* same approach of medications
* scar size varies from 5-15 cm

Exclusion Criteria:

* have cardiac / pacemakers
* have significant health problems
* obese patients (BMI more than 30)
* uncooperative patients

Primary outcomes:
measure: Scar pliability
timeFrame: at baseline and after 3 months of intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Damietta
country: Egypt
facility: Outpatient clinic, Faculty of Physical Therapy, Horus University, Egypt
Study officials:
affiliation: Horus University in Egypt
name: Mohamed Abdelnaser, Assistant lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06711952: German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)
Official title: German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q) and Its Potential Use in Large Cohorts
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alzheimer Disease
Subjective Cognitive Decline
Keywords: Alzheimer's Disease
Subjective Cognitive Decline
German Validation
Lead sponsor: Ludwig-Maximilians - University of Munich
Sponsor class: OTHER
Collaborators: name: Medotrax UG
First posted: 2024-12-02
Enrollment: 300
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The SCD-Q (Subjective Cognitive Decline-Questionnaire) is an established instrument to quantify self-perceived cognitive decline. Both self- and informant-rated versions of the SCD-Q are available. However, the SCD-Q has not been validated in the German language yet. Hence, the investigators aim to validate the self-reported SCD-Q in a clinical sample in Germany.

Detailed description: The SCD-Q is a well-established screening instrument to quantify perceived subjective cognitive decline. In addition to self-perceived cognitive complaints, a 24-item questionnaire for informants is part of the SCD-Q. It demonstrates high sensitivity and lower specificity for detecting dementia and early cognitive changes associated with dementia. However, the questionnaire has not been translated into German or validated. Plasma biomarkers for amyloid and tau pathology, as well as for neurodegeneration and astrocytic activation, have been developed and show promising sensitivity and specificity for detecting Alzheimer's disease (AD). A relevant proportion of biomarker-positive patients does not convert to mild cognitive impairment or Alzheimer's disease dementia during the disease course. Currently, the predictive value of blood biomarkers remains to be clarified, particularly in conjunction with SCD. This study aims to validate the SCD-Q in German and analyze possible connections with biomarkers and (digital) cognitive tests. Follow-up visits are planned.

Eligibility criteria: Inclusion Criteria:

* Medical appointment for dementia diagnostics at the Alzheimer Therapie- und Forschungszentrum
* Provision of signed, written and dated informed consent
* Capacity to give informed consent

Exclusion Criteria:

* dementia in a very advance stage
* Illiteracy

Primary outcomes:
measure: Validation of the SCD-Q in the german language
timeFrame: Baseline
measure: combination of SCD-Q and biomarkers
timeFrame: Baseline
measure: Correlation of SCD-Q with digital cognitive tests and a shortened version of SCD-Q
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: München
country: Germany
facility: Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
state: Bayern
Study officials:
affiliation: Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums
name: Robert Perneczky, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00310752: Evaluation of DermStream(tm) - an Irrigation Product for Chronic Wound Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Venous Insufficiency
Diabetes
Lead sponsor: EnzySurge
Sponsor class: INDUSTRY
First posted: 2006-04-04
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to evaluate the safety of DermaStream(tm) in the management of chronic wounds.

Other goals of this study are to gain feedback from patients and healthcare providers on the ease of use (the ergonomic aspect) of the device, and to make a preliminary evaluation of the efficacy of DermaStream(tm) in chronic wound management.

Detailed description: Until now no expected or unexpected adverse events were occurred

Eligibility criteria: Inclusion Criteria:

* Diabetic ulcer, OR Venous insufficiency ulcer
* Age range: 18-80 years
* Wound max. diameter range: 1.5 - 10 centimeters
* Wound San Antonio assessment system: grade 1 and 2, stage A and B
* Palpable pulses in the Posterior Tibial and the Dorsalis Pedis arteries
* Ankle-Brachial Index \> 0.7 by Doppler
* Wound present for at least 6 weeks
* Wound location: foot or calf, at a location where the device can be attached properly
* Lack of purulent discharge from the wound.

Exclusion Criteria:

* Hypoalbuminemia: Albumin \< 2gr/dl
* Right-side congestive heart failure with edema of legs: +2 or higher
* Renal insufficiency: Cr \> 2 mg/dl
* Abnormal liver function: ALT or AST\>300
* Skin disorders adjacent to the wound, unrelated to the pathology of the wound
* Non-cooperative patient

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zrifin
country: Israel
facility: Vascular Surgery Department, Asaf Harofe Medical Center
Study officials:
affiliation: Asaf Harofe Medical Center
name: Arie Bass, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02180152: Postprandial Walking in Obese Pregnant Women and Perinatal Outcomes - a Multicenter Randomized Clinical Trial
Official title: Postprandial Walking in Obese Pregnant Women and Perinatal Outcomes - a Multicenter Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Obesity
Gestational Diabetes
Preeclampsia
Keywords: Perinatal outcomes
Lead sponsor: Professor Fernando Figueira Integral Medicine Institute
Sponsor class: OTHER
First posted: 2014-07-02
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to verify if postprandial walks are effective in obese pregnant women, as regards to gestational weight gain and typical diseases of that period, as gestational diabetes and preeclampsia. Perinatal outcomes will be observed, such as macrosomia, shoulder dystocia and fetal death.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 40 years;
* Gestational age ≤ 20 weeks, calculated from the last menstrual period and confirmed by the first ultrasound scan;
* Obesity - body mass index ( BMI ) ≥ 30 kg/m2, based on the weight before pregnancy, reported by pregnant women no more than 5 kg below measured at admission to the study;
* Physically inactive - according to the International Physical Activity Questionnaire (IPAC);
* Single pregnancy.

Exclusion Criteria:

* Kidney disease or collagen;
* Previous history of GDM;
* Diabetes type 1 or type 2;
* Hypertensive disorders related to pregnancy;
* Hemodynamic instability;
* Vaginal bleeding;
* Visual, auditory or cognitive impairment.

Primary outcomes:
measure: Weight gain after postprandial walks in obese pregnant women.
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Recife
country: Brazil
facility: Instituto de Medicina Integral Professor Fernando Figueira
state: Pernambuco
Study officials:
affiliation: Instituto de Medicina Integral Professor Fernando Figueira
name: Joao GB Alves, PhD
role: STUDY_DIRECTOR
affiliation: Instituto de Medicina Integral Prof. Fernando Figueira
name: Isabelle EA Pontes, Master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00175552: Ministry of Child and Family Development (MCFD) Interpersonal Psychotherapy for Adolescents (IPT-A) Training Project
Official title: Evaluating the Effectiveness of Different Interpersonal Psychotherapy for Adolescents (IPT-A) Therapist Training Models
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Education of Therapists Treating Adolescent Depression
Keywords: Depression
Adolescents
IPT
Knowledge translation
Psychotherapy
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 24
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Evaluating the Effectiveness of Different Interpersonal Psychotherapy for Adolescents (IPT-A) Therapist Training Models


Eligibility criteria: Inclusion Criteria:

-adolescent undergoing psychotherapy

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Children's and Women's Health Centre of British Columbia
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Elizabeth Baerg Hall, PhD
role: PRINCIPAL_INVESTIGATOR
References: